ESMO: Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel

Company Has Begun Rolling Submission

 
• By Andrew McConaghie
  
John Haanen
John Haanen presented the Phase III study at ESMO 2022, helping to increase confidence in TILs as a viable option in later line care. • Source: ESMO
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas